美股市场个股详情

LIXT Lixte Biotechnology

添加自选

2.8140
+0.0240+0.86%

交易中 05/08 09:30 (美东)

632.95万总市值-1057市盈率TTM

Lixte Biotechnology股票讨论区

登录发表评论

Alex Sual

04/01 22:47

$Lixte Biotechnology(LIXT.US)$ this will hit 4.15 by eod....

Nuyoah

03/28 21:15

$Lixte Biotechnology(LIXT.US)$ 同样地，宝贝，你也可以尽情上涨了，我已经把你抛弃了

70642075

03/28 02:01

$Lixte Biotechnology(LIXT.US)$
How big is the GVHD market?
US$ 2.71 billion
The Graft Versus Host Disease (GVHD) Treatment Market in 2023 is US$ 2.71 billion, and is expected to reach US$ 5.17 billion by 2031 at a CAGR of 8.42%. FutureWise Research published a report that analyzes Graft Versus Host Disease (GVHD) Treatment Market trends to predict the market's growth.Feb 6, 2024

Deutsche Trader

03/27 22:54

$Lixte Biotechnology(LIXT.US)$ loaded 👀✔️

Trytosaveabit

03/27 21:37

$Lixte Biotechnology(LIXT.US)$ WooHoo! 4.33 broke

Trytosaveabit

03/27 21:11

$Lixte Biotechnology(LIXT.US)$ Im looking for next. 4.33, 4.78 and 5.05? Now lets see

Trytosaveabit

03/27 21:03

BOOM

$Lixte Biotechnology(LIXT.US)$

Trytosaveabit

03/27 20:48

Update! Sry was busy!

$Lixte Biotechnology(LIXT.US)$ LIXTE Biotechnology Holdings Publication Pre-Clinical Data In Cancer Discovery Regarding LB-100
Benzinga· 9 mins ago
LB-100 IS SYNERGISTIC WITH WEE1 INHIBITION IN KILLING CANCER CELLS; FINDING OPENS NEW TREATMENT STRATEGY IN ADDITION TO THREE CURRENT LIXTE CLINICAL TRIALS

Trytosaveabit

03/21 20:34

$Lixte Biotechnology(LIXT.US)$ LIXTE recently announced the following significant developments:
• The dosing of the first patient in a Phase 1b/2 clinical trial to assess whether adding LB-100 to GSK's dostarlimab-gxly will enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma (OCCC). The clinical trial was initiated by, and is being conducted at, the University of Texas MD Anderson Cancer Center. LIXTE is providing LB-100, and GSK is providing dostarlimab-...

Trytosaveabit

03/21 20:33

Update

$Lixte Biotechnology(LIXT.US)$ LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
3 MINUTES AGO, 8:30 AM EDT
VIA GLOBENEWSWIRE

暂无评论

分析

分析师评级

暂无数据

目标价预测

暂无数据

热议

美股

综合热度